After an in-depth review, we conclude that FGF23 can be considered a novel biomarker and should be added to the list of previously discovered heart biomarkers such as BNP for the early detection of various highly prevalent cardiovascular diseases, particularly given its direct effect on left ventricular remodeling. The gene discussed is NPPB; the disease is cardiovascular disorder.